Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
Roger BedimoInfectious Disease section, VA North Texas Health Care System, TX, USAAbstract: HIV-infected patients on highly active antiretroviral therapy (HAART) develop a complex of body composition changes known, including peripheral fat loss (lipoatrophy) and central fat accumulation (lipohypertr...
Enregistré dans:
Auteur principal: | Bedimo R |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2011
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/077f68c999454baf9a932f0acba231b4 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Lipodystrophy in HIV patients: its challenges and management approaches
par: Singhania R, et autres
Publié: (2011) -
New and emerging agents in the management of lipodystrophy in HIV-infected patients
par: Eric Bonnet
Publié: (2010) -
Role of darunavir in the management of HIV infection
par: R Monica Lascar, et autres
Publié: (2009) -
Role of raltegravir in the management of HIV-1 infection
par: Okeke NL, et autres
Publié: (2011) -
Profile of darunavir in the management of treatment-experienced HIV patients
par: Cameron Wolfe, et autres
Publié: (2009)